中文 English

OncoAimTM Lung Cancer RNA Fusion Gene Detection Assay

Detection method

The multiplexed targeted sequencing method used with this test, compared to PCR and first-generation sequencing methods, is able to simultaneously detect mutations in multiple genes or regions. More genetic information can be obtained from limited amounts patient samples and quickly.

Test significance

To provide guidance for targeted drugs related to common gene fusions in non-small cell lung cancer, including Sunitinib and Ceritinib.

Product advantage

1) Overcomes detection errors caused by differences in breakpoint positions between fusion genes in the genome.
2) Avoids an excessive amount of DNA sequencing data. Improved sequencing depth and data analysis efficiency.
3) Detects gene fusion for successful transcription of highly expressed RNA variants and prediction of abnormal gene function, which is relevant to the selection of treatment options.
4) Compared with traditional method (FISH), patients positive for fusion genes are more likely to be benefited from targeted drugs1.




Detection of genes

Tumor genes(4)

  • ALK
  • ROS1
  • RET
  • NTRK1

Applicable to cancer patients

The detection is applicable for:
Lung cancer patients treated with target medication, in order to identify the patients with most benefits of certain target treatment.




Test procedure

*Product is for research use only.